US Patent Issued to AstraZeneca UK on Dec. 2 for "Antibodies that bind the spike protein of SARS-CoV-2" (Delaware, Maryland Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,316, issued on Dec. 2, was assigned to AstraZeneca UK Ltd. (Cambridge, Great Britain).

"Antibodies that bind the spike protein of SARS-CoV-2" was invented by Taylor Cohen (Wilmington, Del.), Joe Francica (Wilmington, Del.), Saravan Rajan (Wilmington, Del.), Gilad Kaplan (Gaithersburg, Md.), YingYun Cai (Wilmington, Del.) and Andrew Dippel (Gaithersburg, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-COV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure...